Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study

Nicoletta Ciccarelli, Roberto Cauda, Simona Di Giambenedetto, Annalisa Mondi, Massimiliano Fabbiani, Manuela Colafigli, Alessandro D'Avino, Alberto Borghetti, Roberta Gagliardini, Andrea De Luca, A. De Luca

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

AtLaS was a single-arm pilot study that demonstrated promising efficacy and safety of treatment simplification to a dual regimen with atazanavir/ritonavir + lamivudine in virologically suppressed HIV-positive patients. Here, we report data from the 144 week follow-up.
Original languageEnglish
Pages (from-to)1843-1849
Number of pages7
JournalJournal of Antimicrobial Chemotherapy
Volume70
DOIs
Publication statusPublished - 2015

Keywords

  • antiviral
  • combined antiretroviral therapy
  • dual therapy

Fingerprint

Dive into the research topics of 'Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study'. Together they form a unique fingerprint.

Cite this